Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.
about
BRCAness: finding the Achilles heel in ovarian cancerMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerProgress toward overcoming hypoxia-induced resistance to solid tumor therapyDeoxyribonucleic acid damage-associated biomarkers of ionising radiation: current status and future relevance for radiology and radiotherapyThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapyPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineCellular and molecular mechanisms underlying oxygen-dependent radiosensitivitymRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancerOverexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability.Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.Molecular mechanisms of hypoxia in cancer.Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.Molecular radiobiology: the state of the artRadiation resistance of cancer stem cells: the 4 R's of radiobiology revisited.Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences.Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathwaysTumor hypoxia and genetic alterations in sporadic cancers.Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.Unusual prolongation of radiation-induced G2 arrest in tumor xenografts derived from HeLa cellsSignificance of manipulating tumour hypoxia and radiation dose rate in terms of local tumour response and lung metastatic potential, referring to the response of quiescent cell populations.Mechanisms and consequences of ATMIN repression in hypoxic conditions: roles for p53 and HIF-1.AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Harnessing synthetic lethal interactions in anticancer drug discoveryHypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.Combined hyperthermia and radiotherapy for the treatment of cancer.Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.On the importance of prompt oxygen changes for hypofractionated radiation treatments.BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer.
P2860
Q24630872-E71AE076-4562-4947-A6EF-D81EEAE1C1A4Q26766638-AFA0322D-5EBC-45AE-97CC-4675AD6B6C41Q26778586-8581406D-3B75-4219-8527-D208CD2DD597Q26796405-6BABEE58-D3BB-4EAC-8C1D-FFEB4FCB8D9CQ26866394-58AA581F-0229-4CF8-99A3-7E4B56673A63Q28067724-FA4BC0D0-39BF-4B90-8654-550B0F6BE2A4Q28072204-B57A63CB-ED53-46BF-8DB6-6F4B32D02B1DQ28087499-7051D578-3262-43E4-A188-1EEF1FF68CE9Q28246258-E8C88CB3-17FA-4F6A-BFCA-0C0818025A41Q30922231-ED413DBB-9726-4344-923B-46142F944E44Q33526747-39F33FDC-D16F-4477-9727-3988A2077EEBQ33705108-7490BA00-4102-4A6F-B696-7E7A0E2C2773Q33719652-99086468-CC86-4D2B-8330-4575387878D6Q33848050-A36CEA95-009E-440B-9393-9E859C73CD61Q33889555-74C03216-D485-4F47-A98B-79BA5E26A7CBQ33925368-09F8FE71-5A15-4CFB-8CC6-EF1957289B8BQ34031713-B1A5DEAB-54F5-41F1-B14E-E86FC99A7BF3Q34124274-6156AB96-4215-4F9B-991F-32AB4503055FQ34131280-D2CA64C3-3AC7-4DC3-B8B6-9A86DD11D83EQ34210210-FEC5EE43-A0C5-4639-8605-5F4FB33CEF1EQ34300803-83EBB5F2-B826-4851-BDE5-91CD7AA5E7EBQ34326145-F5436449-2963-4E83-9BFF-D9DACA02927EQ34813119-98E909FD-470D-4D00-AA59-ADED9EDA5424Q35822589-4D57A546-6A13-4983-81B7-2CCC76CC9CBBQ35916654-CB571DB7-7D97-4208-B62A-396FC8D3D2BFQ36262946-2810F4CE-5E3B-4192-BC48-110839164786Q36323808-501E821C-995F-4CCC-A820-661FC78CD7A9Q36580272-64AF867E-3720-48CF-86C3-D6B9168D4125Q36757444-DD899351-F48D-4EBF-8164-82FE41637E9CQ36839571-ACCDDAA7-EFF1-4420-B8FA-78804C9A83A9Q36869865-CE43B49F-462E-4CA3-BD92-D31CFD182CBCQ37081132-D96AE9EC-AF4C-4396-B43E-B4583D56579DQ37122690-430642C0-7E20-4643-8F6C-A9FF4586C96CQ37137456-82FD1732-3D84-4FB4-B8E8-C0D6E2F3A99DQ37148144-BE3DDDED-A439-447A-95A5-61CBCD4CF7A0Q37261476-FEF2B602-AEB7-4366-B519-9903753A487AQ37376797-08E999BC-B425-4D4C-8BC3-5A0FEEFB7B72Q37400573-3B8BAFB1-B29A-4760-BD02-244BC02D7211Q37594158-E08E68BE-A6E0-4282-BD32-680ADFEE46C1Q37594387-DBF85146-DEF0-4888-A5DF-1D890BEF72EF
P2860
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@en
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@nl
type
label
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@en
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@nl
prefLabel
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@en
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@nl
P2093
P50
P1433
P1476
Chronic hypoxia decreases synt ...... esistance and radioresistance.
@en
P2093
Abdellah Belmaaza
Helen Zhao
Norman Chan
Peter M Glazer
Ranjit Bindra
Simon Powell
P304
P356
10.1158/0008-5472.CAN-07-5472
P407
P577
2008-01-01T00:00:00Z